Vestal Point Capital LP Has $33.82 Million Position in GSK plc (NYSE:GSK)

Vestal Point Capital LP increased its stake in shares of GSK plc (NYSE:GSK - Free Report) by 233.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,000,000 shares of the pharmaceutical company's stock after acquiring an additional 700,000 shares during the quarter. GSK makes up about 2.0% of Vestal Point Capital LP's portfolio, making the stock its 19th largest position. Vestal Point Capital LP's holdings in GSK were worth $33,820,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of the stock. Dorsey & Whitney Trust CO LLC increased its holdings in shares of GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after acquiring an additional 278 shares in the last quarter. GC Wealth Management RIA LLC increased its stake in GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock valued at $474,000 after purchasing an additional 353 shares in the last quarter. Jacobi Capital Management LLC increased its stake in GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares in the last quarter. Gladstone Institutional Advisory LLC raised its holdings in GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock worth $413,000 after buying an additional 407 shares during the last quarter. Finally, CENTRAL TRUST Co lifted its stake in shares of GSK by 5.6% in the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock valued at $262,000 after buying an additional 414 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Up 0.2%

NYSE:GSK opened at $37.64 on Monday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a market cap of $77.65 billion, a price-to-earnings ratio of 23.67, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.80. The firm has a 50-day moving average price of $37.39 and a two-hundred day moving average price of $35.96.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. GSK's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 earnings per share. On average, equities analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.48%. GSK's dividend payout ratio (DPR) is currently 86.60%.

Analyst Upgrades and Downgrades

GSK has been the subject of several recent research reports. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Morgan Stanley assumed coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas assumed coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. Finally, StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.